Business context and reporting period
Filing identity: The supplied filing is Catalyst Biosciences, Inc. (Nasdaq: CBIO), not GYRE Therapeutics, Inc. It is a Form 10-K for the fiscal year ended December 31, 2019; it does not report a standalone 2019 Q4 period. Catalyst is a clinical-stage biotechnology company with no products approved for sale and no product-sales revenue.
The company’s principal programs are MarzAA, a subcutaneous Factor VIIa candidate for hemophilia, and DalcA, a subcutaneous Factor IX candidate for hemophilia B. It also has earlier-stage gene therapy and complement programs.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Contract revenue | $0 | $6,000 |
| Research and development expense | $43.9 million | $21.5 million |
| General and administrative expense | $13.4 million | $12.4 million |
| Operating loss | $57.3 million | $33.8 million |
| Net loss | $55.2 million | $30.1 million |
| Net loss per share | $4.60 | $2.68 |
| Cash used in operating activities | $43.6 million | $28.6 million |
Research and development costs rose 104%, principally from manufacturing, higher personnel costs and complement/preclinical work. Net loss increased 84%. Interest and other income fell to $2.1 million from $3.8 million; 2018 included a $1.5 million milestone payment tied to previously sold assets.
At December 31, 2019, cash and cash equivalents were $15.4 million and short-term investments were $61.5 million, totaling $76.9 million. Total assets were $98.6 million, total liabilities $30.2 million, and stockholders’ equity $68.3 million. The filing reports no debt balance or off-balance-sheet arrangements. The company had an accumulated deficit of $258.5 million. No operating margin is meaningful given the absence of product sales and operating revenue.
Cash provided by investing activities was $27.4 million, largely reflecting net maturities of short-term investments; financing activities provided $0.3 million. The $15 million Biogen upfront fee was received in January 2020, recorded as a receivable and deferred revenue at year-end, and recognized as revenue in 2020 upon license transfer.
Material changes and notable developments
- MarzAA’s Phase 2 open-label trial met its primary and secondary endpoints. In nine subjects at final dose levels, mean annualized bleed rate fell from 19.8 before treatment to 1.6 during treatment; seven had no bleeds at their final dose. No anti-drug or neutralizing antibodies were detected in that study.
- DalcA was in a six-person Phase 2b study. Interim results reported in February 2020 showed Factor IX levels above 12%, with levels up to 27%; one participant withdrew, no serious adverse events or anti-drug antibodies were reported, and injection-site reactions were observed.
- In December 2019, Catalyst licensed CB 2782-PEG and other anti-C3 proteases to Biogen for development and commercialization. Terms include a $15 million upfront payment received in January 2020, up to $340 million in potential milestones, tiered royalties up to low double digits, and reimbursement for specified research services. Mosaic is entitled to a double-digit percentage of funds received from Biogen.
- In February 2020, after year-end, Catalyst raised approximately $32 million net by selling 5,307,692 shares at $6.50 per share. The reported share count was 12,076,777 as of February 7, 2020.
Outlook, risks and contingencies
Management stated that year-end cash, cash equivalents and investments were expected to fund operations for at least 12 months from the filing date, while warning that assumptions could prove inaccurate. The company expects materially higher 2020 R&D spending as it advances MarzAA and DalcA and expects continued losses for several years. It may need additional financing; equity issuance could dilute shareholders, and collaborations could require relinquishing rights.
Key risks include clinical failure or delay, limited trial sizes, immunogenicity (including neutralizing antibodies previously observed in two DalcA recipients), regulatory uncertainty, competition, reimbursement and pricing pressure, and reliance on contract manufacturers and research partners. Biogen may terminate its agreement on 60 days’ notice. Potential future obligations include up to $17.5 million in Pfizer milestones plus royalties, up to $19.5 million in ISU milestones plus royalties, and remaining manufacturing work-order payments of $4.6 million to AGC and $0.4 million to Catalent at year-end. These contingent milestone payments are not recorded until achievement becomes probable.
The filing reports no material pending legal proceedings. The independent auditor issued an unqualified opinion on the financial statements and internal controls; management also concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2019.
Important facts for investors to verify
- Confirm the issuer: the provided document is Catalyst Biosciences (CBIO), not GYRE Therapeutics.
- Track final DalcA Phase 2b results and MarzAA’s Phase 3 plans, dose selection, and regulatory requirements; reported trial populations were small.
- Assess cash runway using the subsequent $32 million financing, ongoing burn, planned clinical/manufacturing spend, and timing of Biogen reimbursements and revenue recognition.
- Review the full Biogen and Mosaic agreement terms, including termination provisions, milestone conditions, royalty rates, and Mosaic’s share of proceeds.
- Monitor potential antibody-related safety or efficacy findings, manufacturing execution, competitive developments, and dilution from future financing.